Editor, Ophthalmology Times
4DMT accelerating 4D-150 4FRONT phase 3 program, laying off 25% of staff
July 7th 2025The company notes that the workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials.
Read More
Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191
June 26th 2025ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently with no current FDA-approved therapy
Read More
Valorum Biologics to commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada
June 26th 2025FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization.
Read More
University of Colorado Anschutz Medical Campus Ophthalmology Department receives $40 million gift
June 9th 2025The gift will be used to treat and potentially cure eye diseases such as macular degeneration and glaucoma, increase focus on basic science, and harness artificial intelligence to revolutionize vision care.
Read More
ViGeneron rebrands as VeonGen Therapeutics, announces rare pediatric disease designation for VG801
June 5th 2025VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.
Read More